Sugi Predict

Sugi Predict / Compounds / SCHEMBL19224674

SCHEMBL19224674

SCHEMBL19224674

CCOC(=O)CCCc1nccnc1N

nearest known ligand 0.46

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ CYP1A2 P05177 2/20 0.46
▸ TNF P01375 7/20 0.42
▸ CYP4Z1 Q86W10 1/20 0.42
▸ CYP4F11 Q9HBI6 1/20 0.42
▸ CYP4F12 Q9HCS2 1/20 0.42
▸ CYP4F2 P78329 2/20 0.41
▸ CYP4A11 Q02928 2/20 0.41
▸ DHFR P00374 1/20 0.41
▸ SMN1; SMN2 Q16637 2/20 0.40
▸ ALOX5 P09917 1/20 0.40
▸ CYP3A4 P08684 1/20 0.40
▸ CYP2D6 P10635 1/20 0.40
▸ CYP2C9 P11712 1/20 0.40
▸ CYP2C19 P33261 1/20 0.40
▸ TBXAS1 P24557 1/20 0.39
▸ NR1I2 O75469 1/20 0.39
▸ PGR P06401 1/20 0.39
▸ ADORA3 P0DMS8 1/20 0.39
▸ PTGS2 P35354 1/20 0.39
▸ PDE4D Q08499 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL19255679 0.88 DGKA (0.44) TNFDHFR
SCHEMBL20477208 0.81 CYP4F2 (0.48) CYP1A2CYP4Z1CYP4F11CYP4F12CYP4F2
SCHEMBL19879542 0.78 GABRP (0.35) SMN1; SMN2
SCHEMBL981335 0.76 ALDH1A1 (0.43) CYP1A2TNFCYP4Z1CYP4F11CYP4F12
SCHEMBL941980 0.74 CYP4F2 (0.49) CYP1A2TNFCYP4Z1CYP4F11CYP4F12
SCHEMBL31241618 0.73 TBXAS1 (0.43) CYP1A2TNFCYP4Z1CYP4F2CYP4A11
SCHEMBL27469498 0.73 ALOX5 (0.56) CYP1A2CYP4Z1CYP4F11CYP4F12CYP4F2
SCHEMBL12590777 0.73 CYP1A2 (0.46) CYP1A2TNFCYP4Z1CYP4F11CYP4F12
SCHEMBL10924823 0.73 TLR8 (0.44) DHFR
SCHEMBL2058509 0.72 CYP1A2 (0.42) CYP1A2TNFCYP4Z1CYP4F11CYP4F12

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 34 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20250388601-A1 Compounds, Compositions and Methods DENALI THERAPEUTICS INC. (US) 2025-12-25 — — US disclosed
US-12365695-B2 Fused ring heteroaryl compounds as RIPK1 inhibitors BISICHEM CO., LTD. (KR) 2025-07-22 — — US disclosed
US-12358928-B2 Compounds, compositions and methods DENALI THERAPEUTICS INC. (US) 2025-07-15 — — US disclosed
US-20240150376-A1 Compounds, Compositions and Methods DENALI THERAPEUTICS INC. (US) 2024-05-09 — — US disclosed
US-20230043400-A1 Compounds, Compositions and Methods DENALI THERAPEUTICS INC. (US) 2023-02-09 — — US disclosed
US-20230043400-A1 Compounds, Compositions and Methods DENALI THERAPEUTICS INC. (US) 2023-02-09 — — US disclosed
EP-4010340-A1 FUSED RING HETEROARYL COMPOUNDS AS RIPK1 INHIBITORS Bisichem Co., Ltd. (KR) 2022-06-15 — — EP disclosed
CN-114437105-A Inhibitors of receptor interacting protein kinase 1 戴纳立制药公司 2022-05-06 — — CN disclosed
CN-114206861-A Fused heteroaryl compounds useful as RIPK1 inhibitors 比西切姆有限公司 2022-03-18 — — CN disclosed
CN-109071504-B Inhibitors of receptor interacting protein kinase 1 戴纳立制药公司 2022-03-08 — — CN disclosed
US-20180022759-A1 COMPOUNDS, COMPOSITIONS AND METHODS DENALI THERAPEUTICS INC. 2018-01-25 — — US disclosed
US-20180022759-A1 COMPOUNDS, COMPOSITIONS AND METHODS DENALI THERAPEUTICS INC. 2018-01-25 — — US disclosed
US-9815850-B2 Compounds, compositions and methods DENALI THERAPEUTICS INC. (US) 2017-11-14 — — US disclosed
US-9815850-B2 Compounds, compositions and methods DENALI THERAPEUTICS INC. (US) 2017-11-14 — — US disclosed
US-9815850-B2 Compounds, compositions and methods DENALI THERAPEUTICS INC. (US) 2017-11-14 — — US disclosed
WO-2017136727-A2 COMPOUNDS, COMPOSITIONS AND METHODS DENALI THERAPEUTICS INC. (US) 2017-08-10 — — WO disclosed
WO-2017136727-A2 COMPOUNDS, COMPOSITIONS AND METHODS DENALI THERAPEUTICS INC. (US) 2017-08-10 — — WO disclosed
US-20170226127-A1 COMPOUNDS, COMPOSITIONS AND METHODS DENALI THERAPEUTICS INC. 2017-08-10 — — US disclosed
US-20170226127-A1 COMPOUNDS, COMPOSITIONS AND METHODS DENALI THERAPEUTICS INC. 2017-08-10 — — US disclosed
US-20170226127-A1 COMPOUNDS, COMPOSITIONS AND METHODS DENALI THERAPEUTICS INC. 2017-08-10 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-12365695-B2 Fused ring heteroaryl compounds as RIPK1 inhibitors RIPK1, RIPK3, RIPK4 CYP1A2 3937/4885TNF 639/4885CYP4Z1 3111/4885
US-20250388601-A1 Compounds, Compositions and Methods AURKC, WEE2, ERBB2 CYP1A2 783/4885TNF 4662/4885CYP4Z1 2292/4885
US-20240150376-A1 Compounds, Compositions and Methods PIK3CA, PLK1, PIK3CB CYP1A2 3682/4885TNF 3965/4885CYP4Z1 4320/4885
US-12358928-B2 Compounds, compositions and methods PIK3CA, PLK1, PIK3CB CYP1A2 3682/4885TNF 3965/4885CYP4Z1 4320/4885
US-20230043400-A1 Compounds, Compositions and Methods PIK3CA, PLK1, PIK3CB CYP1A2 3682/4885TNF 3965/4885CYP4Z1 4320/4885
US-20180022759-A1 COMPOUNDS, COMPOSITIONS AND METHODS PIK3CA, PLK1, PIK3CB CYP1A2 3682/4885TNF 3965/4885CYP4Z1 4320/4885
US-20170226127-A1 COMPOUNDS, COMPOSITIONS AND METHODS PIK3CA, PLK1, PIK3CB CYP1A2 3682/4885TNF 3965/4885CYP4Z1 4320/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.